It has been reported that the promoter region of NDRG1 contained a p53 binding site and consequently in human colon cancer (DLD-1-p53) cells, NDRG1 is expressed in a p53-dependent fashion following treatment with DNA-damaging chemotherapeutic drug doxorubicin [21]. Here, NDRG1 is linked to malignant colon neoplasm.